Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Stenocare

0.355

 

DKK

 

-7.31 %

Less than 1K followers

STENO

First North Denmark

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Compare
-7.31%
+7.9%
-28.43%
-51.11%
-51.11%
-87.34%
-94.24%
-97.3%
-97.4%

Stenocare is a Danish supplier of medical cannabis. Stenocare is the first player to have started sale of medical cannabis-based oils in Denmark. The company is now looking towards further European markets for its products. Stenocare is based in Randers, Denmark.

Read more
Market cap
13.63M DKK
Turnover
55.32K DKK
Revenue
4.76M
EBIT %
-695.17 %
P/E
-
Dividend yield-%
-
Financial calendar
21/8
2025

Interim report Q2'25

6/11
2025

Interim report Q3'25

All
Press releases
3rd party
ShowingAll content types
Regulatory press release3 hours ago

Communiqué from the Annual General Meeting of STENOCARE

Stenocare
Third party research5/9/2025, 5:25 AM

Analyst Group Comment on STENOCARE's Q1-report

STENOCARE A/S (STENOCARE or the “Company”) published on May 8th the Company’s Q1-report for 2025.

Stenocare
Regulatory press release5/8/2025, 6:00 AM

STENOCARE: Interim report first quarter 2025

Stenocare

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release5/2/2025, 12:35 PM

Medical Cannabis Made Permanent in Denmark: Major Milestone for Patients and STENOCARE

Stenocare
Regulatory press release4/22/2025, 1:01 PM

Notice to Annual General Meeting in STENOCARE A/S

Stenocare
Third party research4/4/2025, 7:20 AM

Analyst Group Comment on STENOCARE ASTRUM 10-10 Oil Being Approved for Reimbursement in Germany

On April 4th, STENOCARE announced that the innovative ASTRUM 10-10 has obtained for approval for reimbursement in Germany through major health insurance providers. Starting in April 2025, approximately 14 million insured individuals will be eligible ...

Stenocare
Press release4/4/2025, 6:57 AM

Analyst Group: Analyst Group Comment on STENOCARE ASTRUM 10-10 Oil Being Approved for Reimbursement in Germany

Stenocare
Press release4/3/2025, 6:00 AM

STENOCARE ASTRUM 10-10 Oil Product Approved for Reimbursement in Germany

Stenocare
Press release3/31/2025, 6:00 AM

STENOCARE Begins Sales of New CBD100 Oil Product in Denmark

Stenocare
Press release3/28/2025, 12:25 PM

STENOCARE interview with Proinvestor.com - Annual Report 2024

Stenocare
Regulatory press release3/27/2025, 7:01 AM

STENOCARE A/S publishes Annual Report 2024

Stenocare
Third party research3/6/2025, 1:17 PM

STENOCARE: All Focus on Astrum - Analyst Group

STENOCARE A/S (“STENOCARE” or the “Company”) is a medical cannabis trading company with products approved and available for patients in six countries. The Company has recently launched a premium product, Astrum oil, which Analyst Group sees as an important...

Stenocare
Press release3/6/2025, 1:16 PM

Analyst Group: Equity Research Report on STENOCARE - All Focus on Astrum

Stenocare
Third party research2/27/2025, 3:05 PM

Analyst Group's Comment on STENOCARE’s Q4-report Report 2024

STENOCARE A/S (STENOCARE or the “Company”) published on February 27th the Company’s Q4-report for 2024.

Stenocare
Press release2/27/2025, 2:52 PM

Analyst Group: Analyst Group's Comment on STENOCARE’s Q4-report Report 2024

Stenocare
Regulatory press release2/27/2025, 8:04 AM

STENOCARE: Q4 and Annual Financial Statement Release 2024

Stenocare
Press release2/14/2025, 7:56 AM

STENOCARE - The innovative ASTRUM 10-10 product is now available for Australian patients

Stenocare
Press release1/29/2025, 9:52 AM

STENOCARE A/S Embarks on Strategic Transformation with HQ Relocation and Cultivation Facility Exit

Stenocare
Third party research1/23/2025, 6:22 AM

Analyst Group Comment on the Outcome of STENOCARE’s Conditional Rights Issue

On January 22nd, STENOCARE announced the outcome of the conditional rights issue, which was subscribed to approximately 37.7%. Moreover, guaranteed commitments from Exelity AB amounting to 7.3% will be activated to achieve a subscription rate of 45%,...

Stenocare
Press release1/22/2025, 3:27 PM

Analyst Group: Analyst Group Comment on the Outcome of STENOCARE’s Conditional Rights Issue

Stenocare
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team